Advertisements



Xoma"s gevokizumab used to dose first patient in cancer study by Novartis

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2019

Many breast cancer patients can skip chemo, big study finds

Most women with the most common form of early-stage breast cancer can safely skip chemotherapy without hurting their chances of beating the disease, doctors are reporting from a landmark study that used genetic testing to gauge each patient's risk......»»

Category: topSource: foxnewsJun 3rd, 2018

Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150. Inovio Pharmaceuticals, Inc. IN.....»»

Category: dealsSource: nytSep 4th, 2018

The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) read more.....»»

Category: blogSource: benzingaJan 9th, 2019

Intrexon doses first patient in Phase 1/1b study of Acute Myeloid Leukemia drug

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall3 hr. 6 min. ago

Anavex announces first patient dosed in Rett syndrome extension study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 25th, 2019

Bristol-Myers Slips As Regulatory Hiccups Delay Celgene Deal; Liver Cancer Study Faces Setback

Uncertainty over Bristol-Myers Squibb Co (NYSE: BMY)'s impending deal to acquire Celgene Corporation (NASDAQ: CELG) and an adverse clinical trial readout were dragging the shares of the large-cap pharma company lo read more.....»»

Category: blogSource: benzingaJun 24th, 2019

Study links toxic Sept. 11 dust to prostate cancer

New York would adopt the nation's most aggressive carbon emission reduction goals and give new rights to farmworkers under proposals that were moving through the state Legislature Wednesday. With... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkJun 24th, 2019

Bristol-Myers says study of Opdivo in treating rare cancer fails to meet main goals

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJun 24th, 2019

Bristol-Myers offers update on liver cancer trial, to sell Otzela to hasten close of Celgene deal

Bristol-Myers Squibb Co. said Monday a late-stage study of its Opdivo as a treatment for a type of liver cancer failed to meet its main goals. The company said the Phase 3 study called CheckMate -459 evaluating Opdivo versus sorafenib as a .....»»

Category: topSource: marketwatchJun 24th, 2019

Qiagen Clinical Insight selected by Japan"s NCC for cancer patient screening

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 18th, 2019

Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study

Stocks were poised to ease lower on Friday morning......»»

Category: topSource: foxnewsJun 14th, 2019

Progenics doses first patient in Phase 2 clinical study of 1095 radiotherapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2019

Cardiovascular Systems announces enrollment of first patient in REACH PVI study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 11th, 2019

Achieve Life Sciences Reports 74-80% Median Reduction In Smoking In Study

Achieve Life Sciences Inc (NASDAQ: ACHV) a company focused on nicotine addiction, announced positive results Tuesday from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. read more.....»»

Category: blogSource: benzingaJun 11th, 2019

Anavex doses first patient in Phase 2 AVATAR study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 6th, 2019

Amgen"s early-stage study of cancer treatment had "adverse events" in nearly half of its patients

Amgen Inc. said Wednesday data from phase 1 studies of an investigational bispecific T cell engager (BiTE) molecules, updated with investigational AMG 420 results for the treatment .....»»

Category: topSource: marketwatchJun 5th, 2019

Seattle Genetics, Astellas" Cancer Candidate Attains 44% ORR

Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate.....»»

Category: dealsSource: nytJun 4th, 2019

Aduro Stock Crashes After ASCO Updates on Cancer Candidate

Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with No.....»»

Category: dealsSource: nytJun 4th, 2019

Eyenovia enrolls first patient in Phase 3 CHAPERONE study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2019

Incyte treats first patient in FIGHT-302 Phase 3 study of pemigatinib

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2019